Post-authorization Safety Study of Allogeneic Hematopoietic Stem Cell Transplantation in Patients Treated With Mogamulizumab
← catalyst calendarNCT04014374 · readout ≤ 1,289 d
Sponsored by Kyowa Kirin, Inc. (industry) · 4151.T — their whole pipeline →.
Phase
—
Status
Recruiting
Study type
Observational
Enrollment
150estimated
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2019-09-10 | actual | When the study began enrolling |
| Primary completion | Feb 2030 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Feb 2030 | estimated | The whole study's end, after follow-up |
| First posted | 2019-07-10 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2024-07-24 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Leukemia/Lymphoma
- Cutaneous T Cell Lymphoma
- ATLL
Primary outcome
what the primary-completion date above is the date OFAssess toxicities or complications of transplant among patients who were treated with mogamulizumab, alone or in combination
measured one year prior to alloHCT to within 18 months after alloHCT
Permalink · 4151.T's whole pipeline · Catalyst calendar · Every registered study · What changed